Company intelligence / Profile preview
Acrotech Biopharma Inc
East Windsor, New Jersey, United Statesacrotechbiopharma.com ↗
- Ownership
- Private
- Employees
- ~56
- Development stage
- Other
01
Overview
Acrotech Biopharma has several approved drugs, including Ryzneuta™ for chemotherapy-induced neutropenia, pralatrexate and belinostat for peripheral T-cell lymphoma, levoleucovorin for drug intoxication, and melphalan hydrochloride for multiple myeloma. Ryzneuta™ was recently FDA-approved following a global clinical program involving over 1,200 subjects. The company continues to develop additional programs in oncology and hematology.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesBiologicsMonoclonal antibodiesProteins and peptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Evive Biotech/Yifan Pharmaceutical Co., Ltd. – partnership on Ryzneuta™ commercialization in the US
Beyond the preview
Go deeper on Acrotech Biopharma Inc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acrotech Biopharma Inc.